Why the study?
Does nebivolol improve tolerability and reduce blood pressure compared to atenolol in patients with mild-to-moderate essential hypertension?
Does nebivolol improve tolerability and reduce blood pressure compared to atenolol in patients with mild-to-moderate essential hypertension?
Nebivolol provides equivalent blood pressure reduction to atenolol in mild-to-moderate hypertension but with a better tolerability profile and fewer side effects.
Answers are grounded in this paper and cite their sources.
Nebivolol may be preferred over atenolol for better tolerability in hypertension; extends comparative beta-blocker data for practice and future trials.
The objective of this 12-week double-blind randomized multicentre study was to compare the efficacy and tolerability of nebivolol, a recently developed beta-blocking agent with vasodilating properties, to the classical beta-blocker atenolol. After a placebo run-in phase, 205 mild-to-moderate middle-age essential hypertensives were randomized to either nebivolol 5 mg daily (n = 105) or atenolol 100 mg daily (n = 100) over a period of 12 weeks. The primary endpoint of the study was the change in sitting systolic and diastolic blood pressure (SBP and DBP respectively) from baseline to week 12 of treatment. The two drugs induced similar significant antihypertensive effects, the SBP and DBP reduction amounting to -18.2 +/-14.0 and -14.6 +/-7.9 mmHg (mean +/- SD) for atenolol and -19.1 +/-12.9 and -14.8 +/- 7.1 for nebivolol (p < 0.01 for all). This was the case also for standing blood pressure. Sitting and standing heart rate values were significantly reduced by both drugs, the bradicardic response induced by nebivolol treatment being significantly less than atenolol. Distribution of responders and non- responders was similar for nebivolol and atenolol, while the former drug showed a better tolerability profile and a lower incidence of side-effects. These data provide evidence, that, for the same antihypertensive effects, nebivolol shows a better tolerability profile than atenolol and a lower incidence of adverse effects.
No takes yet. Share an insight, caveat, or question.
Grassı et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: